An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 3, 2008, Pages 205-210

  Pae, Chi Un ^a,b   Masand, Prakash S ^a   Peindl, Kathleen ^a   Mannelli, Paolo ^a   Han, Changsu ^a,c   Marks, David M ^a   Patkar, Ashwin A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Catholic University of Korea   (South Korea)

^c Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; FEMALE; HEADACHE; HUMAN; INFORMED CONSENT; INSOMNIA; MAJOR DEPRESSION; MALE; SCORING SYSTEM; SCREENING TEST; SINGLE BLIND PROCEDURE; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

EID: 45849145733     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.v10n0305     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
3. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990;47:935-941
4. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163(suppl 21):30-34
5. Stewart JW, Tricamo E, McGrath PJ, et al. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry 1997;154:31-36
6. Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 1991;48:319-323
7. Stewart JW, McGrath PJ, Rabkin JG, et al. Atypical depression: a valid clinical entity? Psychiatr Clin North Am 1993;16:479-495
8. Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996;37:375-383
9. Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995;152:31-36
10. Quitkin FM, Rabkin JG, Stewart JW, et al. Sleep of atypical depressives. J Affect Disord 1985;8:61-67
11. Parker GB. Atypical depression: a valid subtype? J Clin Psychiatry 2007;68(suppl 3):18-22
12. Eaton WW, Kessler LG. Epidemiological Field Methods in Psychiatry: the NIMH Epidemiological Catchment Area Program. Orlando, Fla: Academic Press; 1985
13. Zisook S, Shuchter SR, Gallagher T, et al. Atypical depression in an outpatient psychiatric population. Depression 1993;1:268-274
14. Stewart JW, Thase ME. Treating DSM-IV depression with atypical features. J Clin Psychiatry 2007;68:e10
15. Pande AC, Birkett M, Fechner-Bates S, et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996;40:1017-1020
16. Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994;32:169-177
17. Søgaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999;13:406-414
18. McGrath PJ, Stewart JW, Janal MN, et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000;157:344-350
19. Falkai P. Mirtazapine: other indications. J Clin Psychiatry 1999;60(suppl 17):36-40; discussion 46-38
20. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998;7:92-95
21. McGrath PJ, Robinson D, Stewart JW. Atypical panic attacks in major depression. Am J Psychiatry 1985;142:1224
22. Forest Pharmaceuticals I. Prescribing information of escitalopram. Available at http://www.frx.com/pi/lexapro_pi.pdf. Accessed Dec 20, 2007
23. Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2007;24:53-61
24. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-131
25. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1767-1775
26. Novick JS, Stewart JW, Wisniewski SR, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005;66:1002-1011
27. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
28. Williams M, Link N, Rosenthal L, et al. Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version.Wilsonville, Ore: Society for Light Treatment and Biological Rhythms; 1988
29. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
30. Beck A, Steer R, Brown G. Manual for Beck Depression Inventory II (BDI-II). San Antonio, Tex: Psychology Corporation; 1996
31. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897
32. Sheehan D. The Anxiety Disease. New York, NY: Scribner and Sons; 1983
33. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545
34. Martiny K, Lunde M, Simonsen C, et al. Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy: a placebo-controlled study. Acta Psychiatr Scand 2004;109:230-234
35. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-381
36. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-336
37. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102
38. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217
39. Lexapro [package insert]. St. Louis, Mo: Forest Pharmaceuticals, Inc.; 2002